基于B群脑膜炎球菌候选抗原的疫苗研发进展  

Review of vaccine development based on candidate antigens of Nesseria meningitidis serogroup B

作　　者：姚崧源(综述) 孙述学(审校) Yao Songyuan;Sun Shuxue(Liaoning Chengda Co.,Ltd.,Shenyang 110026,China;Beijing Cheng Da Tianhe Technology Co.,Ltd.,Beijing 100176,China)

机构地区：[1]辽宁成大生物股份有限公司,沈阳110026 [2]北京成大天和生物科技有限公司,100176

出　　处：《国际生物制品学杂志》2020年第4期185-189,共5页International Journal of Biologicals

摘　　要：流行性脑脊髓膜炎(流脑)是一种由脑膜炎球菌引发的严重呼吸道传染病。随着脑膜炎球菌多糖疫苗和多糖-蛋白结合疫苗的应用,大部分于人群中广泛流行的致病性脑膜炎球菌(血清A、C、W135、Y群)已得到了有效控制。然而,这也导致B群脑膜炎球菌引发的流脑占比增多。此文综述了目前已发现的B群脑膜炎球菌疫苗候选抗原,以及基于这些抗原已经获批和正在研发的B群脑膜炎球菌疫苗,以期帮助研究人员进行新型B群脑膜炎球菌疫苗的研发。Epidemic cerebrospinal meningitis is a serious respiratory infectious disease caused by Neisseria meningitides.With the application of meningococcal polysaccharide vaccines and polysaccharide-protein conjugate vaccines,the epidemic cerebrospinal meningitis caused by serogroups A,C,W135 and Y has been well controlled.However,the proportion of epidemic cerebrospinal meningitis caused by serogroup B has increased as a result.This article reviews potential candidate antigens for Neisseria meningitidis serogroup B and relevant vaccines based on these antigens to help researchers in vaccine development.

关 键 词：奈瑟球菌 脑膜炎 血清B群 脑膜炎双球菌菌苗 候选抗原 

分 类 号：R51[医药卫生—内科学]